As a starting point, testing for EML4‐ALK variants and additional mutations via DNA sequencing is an important analysis that needs to be considered when diagnosing NSCLC patients, albeit at some financial cost, to achieve an effective and personalised therapeutic scheme. This evidence concerns the gene ALK and non-small cell lung carcinoma.